Agenus on a roll in 2015

Agenus Inc., an immunology company developing novel checkpoint modulators, vaccines and adjuvants to treat cancer, acquired Phoslmmune Inc. last week. Phoslmmune is an immunotherapy company that has discovered a new portfolio of cancer neoantigens. Its equity holders will receive an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing, plus milestone payments of up to $35 million in cash and/or stock. This acquisition gives Agenus the capacity to expediate the development of new cancer vaccines and other single-agent immuno-oncology approaches, as well as combination therapies. And the deal most likely caps a healthy year for Agenus, which... Read More »